Accelerated Hyperfractionated Radiotherapy for Locally Advanced Uterine Cervix Cancers

국문 초록 (Abstract)

목 적: 이 연구의 목적은 국소진행된 자궁경부암에서의 가속과분할 방사선치료의 효용성을 평가하기 위함이다.
대상 및 방법: 2000년 5월부터 2002년 9월 사이에 자궁경부암 병기 IIB, IIIB, IVA로 가속과분할 방사선치료를 받은 환
자 45명과 같은 기간 동안 고식적 방사선치료를 받은 병기 IIB, IIIB, IVA 환자 134명이 비교 분석되었다. 가속과분할 방사선치료는 전골반에 대하여 총 30 Gy의 방사선을 1.5 Gy씩 하루 2회, 총 10일에 나누어 조사하였다. 전골반 조사 후
중심 차폐하여 자궁주위 조직에 대하여 총 20 Gy의 방사선을 2 Gy씩 하루 1회, 총 10일에 나누어 조사하였다. 외부방
사선치료가 끝난 후 Cs-137을 이용한 저선량 근접치료를 Point A 기준 55∼60 Gy의 방사선치료를 2회 시행하여, Point
A 기준 총 85∼90 Gy의 방사선 선량이 주어지도록 치료하였다. 고식적 방사선치료 또한 Point A 기준 총 85~90 Gy의
방사선 선량이 주어지도록 치료하였다. 총 치료기간은 가속과분할 치료군의 경우 중앙값이 37일이었으며, 고식적 치료
군은 중앙값 66일이었다. 통계적 분석은 Kaplan-Meyer 법, log-rank test, 그리고 Chi-square test를 통해 이루어졌다.
결 과: 항암치료를 시행했던 환자군에서, 5년 국소제어율은 각각 100.0%와 79.2%로 가속과분할 치료군이 고식적 치
료군에 비해 통계적으로 유의하게 우수한 성적을 보였고(p=0.028), 5년 생존율은 병기 IIB의 큰 종양군에서 가속과분할
치료군이 82.6%으로 고식적 치료군의 62.1%에 비해 통계적으로 유의하게 우수한 성적을 보였다(p=0.074). 두 군간에
있어서 방사선치료로 인한 후기 합병증의 차이는 없었다(p=0.561). 결 론: 항암치료와 동반된 가속과분할 방사선치료는 국소진행된 자궁경부암에서 생존율 및 국소제어율을 높이는데 효과가 있을 것으로 판단된다.

다국어 초록 (Multilingual Abstract)

Purpose: To assess the efficacy of the use of accelerated hyperfractionated radiotherapy (AHRT) for locally
advanced uterine cervix cancers. Materials and Methods: Between May 2000 and September 2002, 179 patients were identified with FIGO stage IIB, IIIB, and IVA cancers. Of the 179 patients, 45 patients were treated with AHRT (AHRT group) and 134 patients were treated with conventional radiotherapy (CRT group), respectively. Patients undergoing the AHRT regimen received a dose of 30 Gy in 20 fractions (1.5 Gy×2 fractions/day) to the whole pelvis. Subsequently, with a midline block, we administered a parametrial boost with a dose of 20 Gy using 2 Gy
fractions. Patients also received two courses of low-dose-rate brachytherapy, up to a total dose of 85∼90
Gy to point A. In the CRT group of patients, the total dose to point A was 85∼90 Gy. The overall treatment
duration was a median of 37 and 66 days for patients that received AHRT and CRT, respectively. Statistical
analysis was calculated by use of the Kaplan-Meier method, the log-rank test, and Chi-squared test. Results: For patients that received cisplatin-based concurrent chemotherapy and radiotherapy, the local control rate at 5 years was 100% and 79.2% for the AHRT and CRT group of patients, respectively (p=0.028). The 5-year survival rate for patients with a stage IIB bulky tumor was 82.6% and 62.1% for the AHRT group and CRT group, spectively (p=0.040). There was no statistically significant difference for severe late toxicity between the two groups (p=0.561). Conclusion: In this study, we observed that treatment with AHRT with concurrent chemotherapy allows a significant advantage of local control and survival for locally advanced uterine cervix cancers.

목차 (Table of Contents)

• Introduction
• Materials and Methods
• Results
• Discussion

참고문헌 (Reference)

• 1 Komaki R, "Twice-daily fractionation of external irradiation with brachytherapy in bulky carcinoma of the cervix. phase I/II study of the radiation therapy oncology group 88-05" 73 : 2619-2625, 1994
• 2 Perez CA, "Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix" 41 : 307-317, 1998
• 3 Withers HR, "The hazard of accelerated tumor clonogen repopulation during radiotherapy" 27 : 131-146, 1988
• 4 Fyles A, "The effect of treatment duration in the local control of cervix cancer" 25 : 273-279, 1992
• 5 Suit HD, "The american society of therapeutic radiologists presidential address: October 1981. potential for improving survival rates for the cancer patient by increasing the efficacy of treatment of the primary lesion" 50 : 1227-1234, 1982
• 6 Fletcher GH, "Squamous cell carcinoma of the uterine cervix: treatment technique according to size of the cervical lesion and extension"
• 7 Marcial VA, "Split-course versus continuous pelvis irradiation in carcinoma of the uterine cervix: A prospective randomized clinical trial of the radiation therapy oncology group" 9 : 431-436, 1983
• 8 Johnson RJ, "Sequential study on the effect of the addition of hyperbaric oxygen on the 5 year survival rates of carcinoma of the cervix treated with conventional fractional irradiations" 120 : 111-117, 1974
• 9 Saibishkumar EP, "Results of a phase II trial of concurrent chemoradiation in the treatment of locally advanced carcinoma of uterine cervix: an experience from india" 92 : E7-12, 2005
• 10 Clark BG, "Rectal complications in patients with carcinoma of the cervix treated with concomitant cisplatin and external beam irradiation with high dose rate brachytherapy: a dosimetric analysis" 28 : 1243-1250, 1994
• 11 Kil WJ, "Rdiotherapy results in stage IIB uterine cervix cancer" 19 : 345-352, 2001
• 12 Lanciano R, "Randomized comparison of weekly cisplatin or protracted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: a gynecologic oncology group study" 23 : 8289-8295, 2005
• 13 Whitney CW, "Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a gynecologic oncology group and southwest oncology group study" 17 : 1339-1348, 1999
• 14 Leibel S, "Radiotherapy with or without misonidazole for patients with stage IIIB or stage IVA squamous cell carcinoma of the uterine cervix: preliminary report of a radiation therapy oncology group randomized trial" 13 : 541-549, 1987
• 15 Williams MV, "Radiation induced renal damage in mice: Influence of fraction size" 10 : 885-893, 1984
• 16 Kim RY, "Radiation alone in the treatment of cancer of the uterine cervix: analysis of pelvic failure and dose response relationship" 17 : 973-978, 1989
• 17 John M, "Preliminary results of concurrent radiotherapy and chemotherapy in advanced cervical carcinoma: a phase I-II prospective intergroup NCOG-RTOG study" 37 : 1-5, 1990
• 18 Morris M, "Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer" 117-1143, 1999
• 19 Eifel PJ, "Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG)" 22 : 872-880, 2004
• 20 Maor MH, "Neutron therapy in cervical cancer: results of a phase III RTOG study" 14 : 885-891, 1988
• 21 Chun M, "Modified partial hyperfractionation in radiotherapy for bulky uterine cervical cancer: Reduction of overall treatment time" 47 : 923-977, 2000
• 22 Kuske RR, "Mini-colpostats in the treatment of carcinoma of the uterine cervix" 14 : 899-906, 1988
• 23 Fowler JF, "Loss of local control with prolongation in radiotherapy" 23 : 457-467, 1992
• 24 Nakano T, "Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix" 101-, 2005
• 25 Perez CA, "Effect of tumor size on the prognosis of carcinoma of the uterine cervix treated with irradiation alone" 69 : 2796-2806, 1992
• 26 Saunders MI, "Continuous, hyperfractionated, accelerated radiotherapy (CHART) in non-small cell carcinoma of the bronchus" 19 : 1211-1215, 1990
• 27 Saunders M, "Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial" 161-165, 1997
• 28 Rose PG, "Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer" 1144-1153, 1999
• 29 Peters WA 3rd, "Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix" 18 : 1606-1613, 2000
• 30 Keys HM, "Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma" radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma 340 : 11544-1103, 1999
• 31 Denekamp J, "Changes in the rate of repopulation during multifraction irradiation of mouse skin" 46 : 381-387, 1973
• 32 Perez CA, "Carcinoma of the uterine cervix. I. impact of prolongation of overall treatment time and timing of brachytherapy on outcome of radiation therapy" 32 : 1275-1288, 1995
• 33 Ward AJ, "Carcinoma of the cervix: results of a hyperbaric oxygen trial associated with the use of the cathetron" 30 : 383-387, 1979
• 34 Montana GS, "Carcinoma of the cervix, stage III. results of radiation therapy" 57 : 148-154, 1986
• 35 Fletcher GH, "Cancer of the uterine cervix. janeway lecture, 1970" 111 : 225-242, 1971
• 36 Jae-Gab P, "Cancer Incidence of Korea 1999-2001" Ministry of Health and Welfare 157-, 2005
• 37 Piver MS, "Blumenson L.Hydroxyurea: a radiation potentiator in carcinoma of the uterine cervix, randomized double-blind study." 147 : 803-808, 1983
• 38 Stryker JA, "Bladder and rectal complications following radiotherapy for cervix cancer" 29 : 1-11, 1988
• 39 Withers HR, "Biologic basis for altered fractionation schemes" 55 : 2086-2095, 1985
• 40 Ang KK, "Altered fractionation schedules, Principles and Practice of Radiation Oncology. 4th ed." Lippincott Co. 337-356, 2004
• 41 MacLeod C, "Accelerated hyperfractionated radiotherapy for locally advanced cervix cancer" 44 : 519-524, 1999
• 42 Withers HR, "A new isoeffect curve for change in dose per fraction" 1 : 187-191, 1983